Literature DB >> 8156510

Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients.

R M Thomas1, J H Baybick, A M Elsayed, L H Sobin.   

Abstract

BACKGROUND: Gastric carcinoids are uncommon, and are unlike carcinoids at other gastrointestinal sites, clinically and pathologically.
METHODS: The authors studied specimens from 104 patients with gastric carcinoid, with study emphasis being placed on pathologic features, immunohistochemistry, clinical associations, and prognostic factors.
RESULTS: The average age of the 47 male patients and 57 female patients was 61 years. Twenty-seven patients had chronic atrophic gastritis, 12 had pernicious anemia, and 6 had hypergastrinemia; no patient had carcinoid syndrome. Most of the tumors were confined to the mucosa and submucosa. Lymph node metastases were present in only one patient. The tumors were argyrophilic in 84% and argentaffin in 14%. Chromogranin tested positive in all patients; serotonin was detected in one-third; other hormones were much less common. Gastrin-positive tumors were antral. Of the 62 patients with follow-up, 44 were alive without disease, 4 were alive with disease, and 14 were dead (4 died of carcinoid-related disease). None of the deceased had pernicious anemia or hypergastrinemia. The tumors in patients with a fatal outcome were 2 cm or larger.
CONCLUSION: Gastric carcinoids generally are indolent tumors, particularly when associated with pernicious anemia or hypergastrinemia or when smaller than 2 cm. Chromogranin is the most sensitive marker.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8156510     DOI: 10.1002/1097-0142(19940415)73:8<2053::aid-cncr2820730807>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Gastric carcinoids: between underestimation and overtreatment.

Authors:  Sara Massironi; Valentina Sciola; Matilde-Pia Spampatti; Maddalena Peracchi; Dario Conte
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

2.  Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature.

Authors:  J Soga
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

3.  Lymph node metastasis from gastric carcinoid tumors occurring concomitantly with gastric adenocarcinomas and atrophic gastritis.

Authors:  Rocco Roberto Pidoto; Arnaud Piquard; Fausto Famá; Olivier Saint Marc
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

4.  Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids.

Authors:  D Granberg; E Wilander; M Stridsberg; G Granerus; B Skogseid; K Oberg
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

5.  Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Authors:  Hong Shen; Zhuo Yu; Jing Zhao; Xiu-Zhen Li; Wen-Sheng Pan
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

6.  Immunocytochemical localization of prohormone convertase 1/3 and 2 in gastrointestinal carcinoids.

Authors:  T Tomita
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

7.  Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.

Authors:  Kurt Borch; Bo Ahrén; Håkan Ahlman; Sture Falkmer; Göran Granérus; Lars Grimelius
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

8.  Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Authors:  Andreas Tartaglia; Guida M Portela-Gomes; Kjell Oberg; Paolo Vezzadini; Maria P Foschini; Mats Stridsberg
Journal:  Virchows Arch       Date:  2006-01-12       Impact factor: 4.064

Review 9.  Diagnosis and treatment of gastric neuroendocrine tumours.

Authors:  Ursula Plöckinger
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 10.  Chronic hypergastrinemia: causes and consequences.

Authors:  Lori A Orlando; Lane Lenard; Roy C Orlando
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.